Compare TWST & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TWST | HCM |
|---|---|---|
| Founded | 2013 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.7B |
| IPO Year | 2018 | N/A |
| Metric | TWST | HCM |
|---|---|---|
| Price | $47.08 | $15.10 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 8 | 1 |
| Target Price | ★ $48.75 | $13.75 |
| AVG Volume (30 Days) | ★ 1.5M | 23.0K |
| Earning Date | 05-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $376,572,000.00 | N/A |
| Revenue This Year | $18.89 | N/A |
| Revenue Next Year | $15.28 | $16.12 |
| P/E Ratio | ★ N/A | $5.49 |
| Revenue Growth | ★ 20.32 | N/A |
| 52 Week Low | $23.30 | $11.51 |
| 52 Week High | $57.88 | $19.50 |
| Indicator | TWST | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 47.88 |
| Support Level | $25.67 | $14.69 |
| Resistance Level | N/A | $15.61 |
| Average True Range (ATR) | 3.06 | 0.38 |
| MACD | -0.43 | -0.02 |
| Stochastic Oscillator | 30.76 | 43.40 |
Twist Bioscience Corp is a synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's proprietary semiconductor-based manufacturing process synthesizes DNA on silicon rather than traditional plastic plates, enabling the production of high-quality synthetic DNA faster, more affordably, and at scale. This platform overcomes conventional inefficiencies, supports cost-effective, high-throughput synthesis, and allows researchers to accelerate innovation. Geographically, the company operates across the Americas, EMEA, and APAC, deriving the majority of its revenue from the Americas.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.